PepGen Inc SEC Filings

PepGen Inc. executive Paul Streck, EVP and Head of R&D, had 1,879 shares of common stock sold on March 4, 2026 at prices between $6.23 and $6.29. The footnote explains these shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding due on vested restricted stock units, and the sale is described as non-discretionary under a Rule 10b5-1 "binding contract". After these transactions, Streck directly holds 76,226 common shares.

PepGen Inc. Chief Financial Officer Noel Donnelly had a total of 2,084 shares of common stock automatically sold on March 4, 2026 in open-market transactions at prices of $6.23 and $6.325 per share. According to the disclosure, these mandatory sell-to-cover trades were executed by the company to satisfy minimum statutory tax withholding due upon vesting and settlement of restricted stock units under a pre-existing Rule 10b5-1 compliant agreement, rather than as discretionary sales by the executive. Following these transactions, Donnelly directly holds 111,603 shares of PepGen common stock.

PepGen Inc. president and CEO James G. McArthur reported automatic sales of common stock tied to restricted stock units. On the transactions date, a total of 5,275 shares were sold at prices of $6.23 and $6.325 per share to cover minimum statutory tax withholding obligations, and he held 296,326 shares afterward. The filing states these sales were made under a mandatory sell-to-cover provision and did not represent discretionary trades.

PepGen Inc. updated its corporate presentation to spotlight PGN-EDODM1, an investigational therapy for myotonic dystrophy type 1 (DM1) built on its EDO oligonucleotide delivery platform. The company reports dose-dependent, single-dose splicing correction in a Phase 1 study, with mean improvements of 12.3% at 5 mg/kg, 29.1% at 10 mg/kg, and 53.7% at 15 mg/kg, alongside generally well-tolerated safety with mainly mild to moderate adverse events. A multinational Phase 2 multiple-ascending-dose FREEDOM2-DM1 trial is under way, though a partial clinical hold has recently been placed by the U.S. FDA. PepGen highlights upcoming clinical readouts in Q1 2026 for the 5 mg/kg cohort and in the second half of 2026 for the 10 mg/kg cohort, and states it has cash runway into the second half of 2027.

PepGen Inc. describes its efforts to develop PGN-EDODM1, an oligonucleotide therapy for myotonic dystrophy type 1 using its Enhanced Delivery Oligonucleotide platform. In a completed Phase 1 trial, single doses up to 15 mg/kg produced dose-dependent skeletal muscle splicing improvements, reaching a mean 53.7% at 15 mg/kg, with mainly mild or moderate side effects and transient kidney biomarker changes.

A multinational Phase 2 study, FREEDOM2, is dosing 5 and 10 mg/kg cohorts, but the FDA has placed a partial clinical hold tied to questions about preclinical pharmacology and toxicology. PepGen plans to provide additional analyses, including newly unblinded Phase 1 data, while continuing enrollment ex‑U.S. Data from the 5 mg/kg cohort are expected in the first quarter of 2026 and from the 10 mg/kg cohort in the second half of 2026. The company reports an aggregate market value of non‑affiliate equity of $16.9 million based on the Nasdaq closing price as of June 30, 2025, and 69,115,292 common shares outstanding as of February 26, 2026.

PepGen Inc. reported 2025 results showing a net loss of $89.7 million, or $(2.12) per share, on operating expenses of $93.6 million. Cash, cash equivalents and marketable securities were $148.5 million as of December 31, 2025, which the company believes will fund operations into the second half of 2027.

The company highlighted Phase 1 data for PGN-EDODM1 in DM1, with mean splicing correction of 12.3%, 29.1% and 53.7% at 5, 10 and 15 mg/kg, and generally well-tolerated safety. At the same time, the FDA placed a partial clinical hold on the U.S. Phase 2 FREEDOM2-DM1 trial related to preclinical pharmacology and toxicology, while dosing at 10 mg/kg continues in Canada and the UK and regulatory clearances have been obtained in South Korea, Australia and New Zealand.

Vittiglio Joseph reported acquisition or exercise transactions in this Form 4 filing.

PepGen Inc. reported that Chief Business & Legal Officer Joseph Vittiglio received new equity awards. He was granted stock options for 120,000 shares of PepGen common stock, which vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, subject to his continued service.

He also received 30,717 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in equal annual installments over four years, beginning on March 1, 2027, contingent on continued service. Following the RSU grant, he directly owned 65,717 shares of common stock.

PepGen Inc. reported new equity awards for Chief Technical Officer Kasra Kasraian. On March 1, 2026, he received stock options for 135,000 shares at an exercise price of $0.00 per share and 34,557 restricted stock units, each representing one share of common stock upon vesting.

The RSUs vest in four equal annual installments starting on March 1, 2027, contingent on continued service. The option vests 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, also conditioned on continued service.

PepGen Inc. executive Paul Streck, EVP and Head of R&D, reported awards of equity-based compensation. He received stock options covering 196,500 shares at an exercise price of $0.00 per share and 50,300 shares of common stock in the form of restricted stock units. The RSUs vest in equal annual installments over four years starting on March 1, 2027, while the option vests 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, in each case conditioned on continued service.